Evan Feinberg
Researcher · Founder
Now Founder, Genesis Molecular AI (formerly Genesis Therapeutics)
Latest on AI4S.fyiFunding · Aug 21, 2023 · founderGenesis Molecular AI (formerly Genesis Therapeutics) · Series B · $200MPhotos come from each person's X account, their own site, lab or team page, a conference page that lists them as a speaker in the same role, or Wikimedia Commons under the licence credited, so some may be out of date. Anyone can ask for theirs to be replaced or removed. Contact →
Affiliations
Current
Also named in the companies' announcements: Stanford
Current roles come from these dated records, not from the bio below. Each links the page it was read from.
About
Evan Feinberg is co-founder and chief executive of Genesis Molecular AI, which he founded in 2019 to develop the AI and simulation research he did in Vijay Pande's lab at Stanford, including PotentialNet, a physics-based machine learning framework for drug targets with little data. He holds a BS in applied physics from Yale and a PhD in computational biophysics from Stanford.
Read on 2026-09-29; for current roles see Affiliations above. Read at: genesis.ml ↗ · convention.bio.org ↗
Selected work
- PotentialNet for Molecular Property Prediction ↗
Graph convolutional networks for predicting molecular properties, including protein-ligand binding.
Each byline was read on the paper itself. Only people on this record are named, not the full author list, and a shared byline does not say who did which part.
Founded
Genesis Molecular AI (formerly Genesis Therapeutics)Drug discovery · 2019 · 2 rounds on record · disclosed $252M · Series B $200MBackground: Stanford, Pande Lab (PhD) (as the company's own announcements put it)
Co-founders: Ben Sklaroff
Nothing else on the record names them yet.
Something wrong or missing on this page? Tell me and it will be fixed or removed. Contact →